Axsome Unveils New Findings on Auvelity and AXS-05 for Central Nervous System (CNS) Disorders at ASCP Conference
Portfolio Pulse from Benzinga Newsdesk
Axsome Therapeutics (NASDAQ:AXSM) announced new findings on its CNS disorder treatments, Auvelity and AXS-05, at the 2024 ASCP Annual Meeting. The data highlights improvements in anhedonic symptoms and daily function in MDD patients using Auvelity, and the clinical profile of AXS-05 for Alzheimer's disease agitation.
May 28, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Axsome Therapeutics presented new data on Auvelity and AXS-05 at the 2024 ASCP Annual Meeting, showing significant improvements in MDD and Alzheimer's disease agitation.
The new data presented at a major conference highlights the efficacy of Axsome's products, which could boost investor confidence and positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100